Singapore markets closed

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
16.47-0.96 (-5.49%)
As of 10:07AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close17.43
Bid17.10 x 800
Ask17.18 x 1100
Day's range15.86 - 17.41
52-week range3.21 - 18.33
Avg. volume10,262,408
Market cap4.608B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript February 28, 2024 Iovance Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.45 EPS, expectations were $-0.44. Iovance Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]

  • Zacks

    Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates

    Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -2.27% and 61.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?


    Iovance Biotherapeutics Inc (IOVA) Reports Q4 and Full Year 2023 Financial Results

    Net Loss: Increased to $116.4 million in Q4 and $444.0 million for the full year, reflecting investment in commercial and development activities. Research and Development: R&D expenses rose to $87.5 million in Q4, driven by manufacturing and clinical trial costs. Selling, General and Administrative Expenses: Increased to $29.9 million in Q4, supporting business growth and Proleukin integration.